ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

February 8, 2018

Responsive image

SAN FRANCISCO and RARITAN, N.J., Feb. 8, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new findings from the Phase 3 SPARTAN clinical trial that showed treatment with ERLEADA™, an investigational, next-generation1 androgen receptor…

Category: Precious Metals